Physician profile
Simon Lo
NPI 1255368874
$120,481.86
in general payments reported to CMS, 2019-2025
12 companies · $6,417 in 2025
The $6,417 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2022: $24K · 2023: $33K · 2024: $57K · 2025: $6,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $58K · Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $4,091 · Food and Beverage: $2,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $58,087.33 |
| Consulting Fee | $19,040.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,115.00 |
| Travel and Lodging | $4,090.92 |
| Food and Beverage | $2,275.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $83,621.57 | 2022-2025 | Visiglide, Hanarostent Lowaxtm Duodenum/Pylorus(Nnn), Hanarostent Esophagus Tts(Ccc) |
| Olympus Corporation | $18,727.81 | 2023-2024 | Single Use Biliary Balloon Dilator |
| Boston Scientific Corporation | $13,905.21 | 2019-2025 | Biliary Stent Introducer, General - Biliary Devices, Spyglass |
| Olympus America INC. | $3,106.31 | 2022-2023 | Disposable Biopsy Forceps |
| Olympus Medical Systems Corporation | $335.00 | 2024 | |
| Fujifilm Healthcare Americas Corporation | $308.44 | 2025 | |
| Micro-Tech Endoscopy USA, INC. | $169.50 | 2019 | |
| Amgen INC. | $162.00 | 2025 | Uplizna |
| Covidien Lp | $91.59 | 2019 | |
| Abbvie INC. | $28.87 | 2025 | |
| Gilead Sciences, INC. | $13.12 | 2024 | |
| Travere Therapeutics, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.